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Abstract: The incidence and mortality of hepatitis B virus (HBV)-associated hepatocellular carcinoma
(HBV-HCC) is an intractable public health problem in developing countries that is compounded by
limited early detection and therapeutic options. Despite the early promise of utilizing the regulatory
role of miRNA in liver cancer, this field remains largely in the work-in-progress phase. This exploratory
review paper adopts a broad focus in order to collate evidence of the regulatory role of miRNA in each
stage of the HBV-HCC continuum. This includes the regulatory role of miRNA in early HBV infection,
chronic inflammation, fibrosis/cirrhosis, and the onset of HCC. The paper specifically investigates
HBV dysregulated miRNA that influence the expression of the host/HBV genome in HBV-HCC
pathogenesis and fully acknowledges that this does not cover the full spectrum of dysregulated
miRNA. The sheer number of dysregulated miRNA in each phase support a hypothesis that future
therapeutic interventions will need to consider incorporating multiple miRNA panels.
Keywords: regulatory; role; dysregulated; miRNA; hepatitis B infected hepatocellular carcinoma;
HBV-HCC continuum
1. Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC)
An estimated 841,080 new liver cancers (LCs) were diagnosed worldwide in 2018, with
hepatocellular carcinoma (HCC), the most common histological subtype, accounting for 75% to
90% of LCs [1]. A 12.4% increase of LC was recorded between 2008 (696,000) to 2012 (782,000) [2]
and [3] 7.6% between 2012 and 2018 (841,080) [1]. HCC is listed globally as a leading cancer in men
and women [4], with a recent report indicating that 83% of new cases diagnosed occurred in less well
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developed countries in East and south Eastern Asia and Western and Central Africa [5] [GLOBOCAN
2018 (http://gco.iarc.fr), accessed on 28 October 2019].
HBV and hepatitis C virus (HCV) infection is linked with more than 90% of all HCC incidence in
developing countries compared to 40% in developed countries, with HBV being the major contributor
in 66% of the cases [6]. According to the estimates of the global burden of disease study, deaths due
to viral hepatitis increased by 63%, from 0.89 million to 1.45 million, between 1990 and 2013 [7,8].
HBV has been coined as “the second most dangerous carcinogen after tobacco” [8,9]. HBV, the
prototype member of the family Hepadnaviridae, is hepatotropic and non-cytopathic. HBV enters
the hepatocyte via the sodium-taurocholate cotransporting polypeptide (NTCP) receptor [10] and
replicates by reverse transcription of a RNA intermediate, the pregenomic RNA (pgRNA). Although
not required for replication of HBV, integration of HBV DNA can occur within the host genome and
this has been implicated in hepatocarcinogenesis [11].
1.1. HBV-HCC Pathogenesis Continuum
HBV infection can result in a cascade of complex interactions between the host and the virus,
which can lead to a spectrum of clinical manifestations including the asymptomatic carrier state, acute
or fulminant hepatitis, and, ultimately, chronic hepatitis with progression to HCC with or without
intermediary cirrhosis [12]. In 95% of infected adults and in only 10% of children, acute infection is
self-limiting, with the virus persisting in 5% and 90% of the cases, respectively [12,13], with the risk of
HCC increasing 100-fold if a patient is positive for both the hepatitis B surface antigen (HBsAg) and
the hepatitis B e antigen (HBeAg). Even in the absence of HBsAg, there is a reduced and yet significant
risk of HCC [14]. As viral load increases, the host immune response, triggered by HBV surface antigens
(HBsAg), elicit T-cell responses accompanied by secondary inflammatory response [14], and an increase
in free radicals, interferon, tumor necrosis factor (TNF), and hepatic injury. Moreover, if integration of
HBV DNA into the host hepatocyte genome occurs, it results in the oncogenic disruption of cellular
genes [15]. This disruption triggers apoptosis, regeneration, and early senescence [16], in addition to
host cell deletions, cis/trans-activation, translocations, the production of fusion transcripts, aberrant
epigenetic changes, and generalized genomic instability [17]. In parallel with these changes, the
continuous destruction of well-differentiated hepatocytes and organized extracellular matrix results
in their eventual replacement with undifferentiated liver stem cells and poorly organized fibrotic
tissue [12].
HBV-HCC pathways typically include aberrant expression in the retinoblastoma-tumor protein 53
(RB1-TP53) suppressor networks, the Wingless-related integration site/beta-catenin (WNT/β-Catenin)
pathway, and the phosphoinositide 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) and Janus
kinase/signal transducer (JAK/STAT) pathways [18,19] (see Figures 1–4).
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Figure 1. HBx-dysregulated miRNA in the P13K/MAPK liver cancer pathway. HBV-specific 
abbreviations include endothelin-1 (Edn-1), HIST METH (histone methylation), Farnesoid X receptor 
(FXRα). 
3.2. Dysregulated MiRNA in the WNT/β-Catenin Pathway in HBV-HCC 
The upregulation of the WNT/β-catenin pathway is a frequent event in early HCC [251]. It yields 
an aggressive phenotype that is implicated in the proliferation, migration, invasion, and survival of 
cancer cells [244]. Figure 2 illustrates some examples of HBx-dysregulated miRNAs and their target 
genes in this pathway. The HBx protein typically plays a role in enhancing WNT and β-catenin 
expression while suppressing the expression of E-Cadherin. WNT signaling, for instance, is not 
modulated as a result of HBx led downregulation of miR-122/148a/b [157,173,174] and Cadherin 
expression is suppressed because these miRNA fail to suppress cadherin suppressors like SNAIL 1 
[174]. HBx-induced upregulation of mIR-21 also enhances WNT signaling because it reduces DCC6 
suppression of WNT signaling [252] and contributes to the suppression of E-cadherin by suppressing 
PDCD4 expression [55]. HBx-upregulated miR-221/-222 also contributes to the suppression of 
cadherin by enhancing ZEB 1/2 via blocking one of its suppressors like TRPS-1 [54,157]. Cadherin 
expression is also suppressed as a result of HBx-induced downregulation of miR-200/-205/-101/34 
that fails to regulate ZEB 1/2 [95,150,190]. HBx-induced downregulation of miR-122 reduces β-
catenin-led transcription in the cytoplasm [156], while HBx upregulation of miR-155 blocks the APC 
tumor suppressor in the WNT pathway, as well as suppresses HBV replication by blocking enhancer 














































Figure 1. HBx-dysregulated miRNA in the P13K/MAPK liver cancer pathway. HBV-specific
abbreviations include endothelin-1 (Edn-1), HIST METH (histone methylation), Farnesoid X receptor
(FXRα).
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Figure 2. Dysregulated miRNA in the WNT/β-catenin liver cancer pathway. HBV-specific 
abbreviations DCC6 (DCC-adaptor protein), DNA METH (DNA methylation), HISTONE METH 
((histone methylation), PPARγ (peroxisome proliferator-activated receptor gamma), EMT (epithelial 
mesenchymal transition). 
3.3. Dysregulated MiRNA in the TP 53 Pathway in HBV-HCC 
The deregulation of multiple p53 pathways is a central event in the progression of HBV-HCC 
[253]. The INK4alpha/ARF locus, that encodes p14(ARF) and p16(INK4alpha) to arrest the cell cycle in 
the p53 and RB pathways, is frequently disrupted in HCC [254]. Figure 3 illustrates how HBx directly 
targets p53 expression [28,241] to influence the expression of miRNAs in this pathway. Typically, the 
HBx protein downregulates miR-26a/-34a/-138/15a/16-1, that fail to modulate cyclinD/CDK 4/6 and 
cyclinE/CDK2 expression [78,168,197,207], as well as miR-122/-Let-7/-34a/-125b/15a/16-1 [78,145,255–
258], that then fail to modulate BCL-2-mediated suppression of CASP9/3-induced apoptosis. 
Similarly, HBx downregulation of miR-101/-125b/-29a/-Let-7 exerts an anti-apoptotic effect by failing 
to modulate MCL-1-mediated suppression of CASP9/3-induced apoptosis [200,255,258,259]. HBx-
induced C-MYC upregulation of miR-17-92 and miR-221/222 also contribute to the E2F-mediated 
downregulation of p21/p27/p57 expression as a regulator of cyclins and cyclin-dependent kinases 








































Figure 2. Dysregulated miRNA in the WNT/β-catenin liver cancer pathway. HBV-specific
abbreviations DCC6 (DCC-adaptor protein), DNA METH (DNA methylation), HISTONE METH
((histone methylation), PPARγ (peroxisome proliferator-activated receptor gamma), EMT (epithelial
mesenchymal transition).
Cells 2019, 8, 1504 5 of 35
Cells 2019, 8, 1504 24 of 40 
 
 
Figure 3. Dysregulated miRNA in the TP53 liver cancer pathway. HBV-specific abbreviations include 
DNA METH (DNA methylation), HISTONE METH (histone methylation). 
3.4. Dysregulated MiRNAs in the JAK/STAT Pathway in HBV-HCC 
The aberrant methylation in the CpG island of the SOCS-1 gene is a common feature in HBV-
HCC and its silencing demonstrates its important tumor suppressor role in the JAK/STAT pathway 
[260]. Suppressor of cytokine signaling (SOCS-1) switches this signaling ‘off’ by means of its direct 
interaction with (JAK). The loss of function of SOCS-1 is a common feature in HCC and the HBx-
mediated upregulation of miR-155 is a contributing factor in HBV-HCC (see Figure 4) [261,262]. HBx 
upregulated miR-221/-203 contribute to a reduction in SOCS3 regulation of JAK/STAT signaling 
[263]. HBx also downregulates Let-7, which reduces its modulation of IL-6 induced activation of 
JAK/STAT signaling and mTOR mediated transcription of oncogenic proteins like C-MYC/MCL-1 
[145,250,264]. However, HBx upregulation of miR-7 [241], has been demonstrated as a control by way 
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Figure 3. Dysregulated miRNA in the TP53 liver cancer pathway. HBV-specific a breviations include
DNA ETH (DNA ethylation), IST E ET (histone ethylation).
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Figure 4. Dysregulated miRNAs in the JAK/STAT liver cancer pathway. METH (Methylation) C/EBP 
(CCAAT/enhancer-binding protein) Enh11 (enhancer 11). 
4. Discussion and Conclusions 
This exploratory review deliberately adopts a broad focus to demonstrate the complex 
regulatory role of miRNAs in the HBV-HCC continuum. Multiple knowledge gaps, exposed in this 
paper, prompt further research, to clarify the complex regulatory roles of the same miRNA across the 
HBV-HCC continuum. In addition, numerous miRNA target the same genes and cascades of miRNA 
respond to injury and disease with differing levels of expression in tissue, serum and cell-lines. 
Circulating miRNA, for instance, may originate from different cells (e.g., blood-immune) rather than 
an HBV or cancer specific origin by way of secretion or cell death [265–267]. The broad focus of the 
paper is, therefore, specifically adopted to highlight this complexity rather than to explain it. The key 
focus of this exploratory review was, therefore, to illustrate the multiplicity of dysregulated miRNA 
in clearly defined stages of pathogenesis rather than to attempt to try and explain their role in 
mediating multiple targets or summarize their role across every stage of HCC pathogenesis (see miR-
122/-21). A key limitation of the study, therefore, is that it conveys an overly simplistic role of specific 
miRNA in HBV-HCC pathogenesis. 
The potential roles of HBx downregulated miR-124, illustrates this limitation (see Table 3). Its 
various roles could include interaction with lncRNA-MALAT1 to regulate HBx-induced cancer stem 
cell properties in HepG2 through PI3K/AKT signaling [268]. miR-124 also suppresses cell 
proliferation and tumor growth in HCC in vitro and in vivo models by direct targeting STAT3 and 
PIK3CA thereby repressing both JAK/STAT and PI3K/AKT pathways [164]. Other studies 
demonstrate that miR-124 can suppress cell proliferation in HCC by targeting PIK3CA [269], as well 
as extracellular matrix protein laminin gamma 1 (LAMC1), which is a key feature in HCC progression 
[270]. However, LAMC1 mRNA promote malignancy by competing with miR-124 by binding with 
CD151 [270] and the overexpression of LAMC1 promotes HCC progression pathway by interaction 
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Figure 4. Dysregulated miRNAs in the JAK/STAT liver cancer pathway. METH (Methylation) C/EBP
(CCAAT/enhancer-binding protein) Enh11 (enhancer 11).
This paper specifically adopts a broad, exploratory review of the regulatory role of HBV
dysregulated miRNA in the HBV-HCC continuum and miRNA dysregulation may provide a means of
screening HBV carriers and developing biomarkers and alternate therapeutic opti ns.
1.2. The Deregulation of MiRNA in HBV-HCC Continuum
MicroRNA (miRNA) act as post-transcriptional gene silencers that collectively reduce or inhibit
their target mRNA expression, thereby playing a homeostatic role that fine tunes the translation of
proteins. The ancillary role of miRNA, as mild suppressors, has been explained by the inherently
stochastic nature of gene transcription and environmental fluctuations [20]. In the case of transient
reaction to environmental conditions, miRNA quantity become temporarily dysregulated until
homeostasis is restored [21]. In the case of the continuum from asymptomatic HBV infection leading to
HCC, multiple miRNA become increasingly permanently dysregulated (Tables 1–4) as a result of HBV
infection, epigenetic changes [22], inflammation [23], fibrosis [24], cirrhosis [16], and the onset of HCC.
The increasing level of dysregulation in the HBV-HCC continuum is illustrated in a study that showed
37 miRNA deregulated in otherwise healthy controls (HC), 77 in asymptomatic HBV carriers (ASC),
101 in chronic hepatitis B infection (CHB) (Table 1), and 135 in acute liver failure (ALF) [25]. In general,
dysregulated miRNA in the HBV-HCC continuum fall into two major categories, namely, those that
target HBV transcripts and those that target the host cell genome expression.
2. MiRNA Dysregulation in the HBV-HCC Continuum
This section illustrates the regulatory role of HBV d sregulated miRNA in the different stages of
the HBV-HCC continuum (Tabl 1–4). A brief description of each stage is provided before des r bing
the regulato y role of miRNA.
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2.1. Early/Chronic HBV Infection
In this stage the pivotal role of HBV, in cases where viral clearance does not occur, appears mainly
to be due to the continuous destruction of hepatocytes by T-cells, which attempt to eliminate the
infection in conditions of chronic inflammation and increasing oxidative stress [18]. If viral clearance
does not occur, patients that progress to CHB will elicit a weak peripheral cytotoxic T-lymphocyte (CTL)
response. Typically, an activated humoral response in CHB involves the production of interleukin-4
(IL-4), IL-5, and IL-10 secreted by type-2 helper T lymphocytes that promote antibody production
rather than viral clearance. It is also hypothesized that low levels of intrahepatic HBV-specific CTLs
are the cause of hepatic inflammation flares that occur in CHB patients without viral clearance [26].
Host cell miRNA modulate HBV expression by either targeting own cell transcription factors required
for HBV genome transcription or by directly binding to HBV transcripts [13]. Many host cell miRNAs
are also modulated by HBV proteins in order to ensure the persistence and replication of the virus.
MiRNA Regulating HBV Genome Expression
HBV genome replication and survival is self-managed as a result of modulating (up/down) both
host cell miRNA expression, as well as coding for its own miRNA [27]. The hepatitis B virus x protein
(HBx), for example, blocks p53 stimulated miR-34 expression in hepatocytes leading to the upregulation
of macrophage-derived chemokine (CCL22) that stimulates regulatory T-cells (Tregs) that, in turn,
block effector T-cells allowing HBV expression to increase [28,29] HBV genome transcription or by
directly binding to HBV transcripts [13] (see Scheme 1, pathway 1).
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Schematic 1. HBx-mediated miRNA pathways in early/chronic HBV infection. CCL22: C-C motif 
chemokine 22; SOCS1: Suppressor of cytokine signaling 1; C/EBP: CCAAT/enhancer-binding protein; 
HO1: heme oxygenase 1; CREB: c-AMP-response element binding protein. 
2.2. HBV-Induced Inflammation Pathways 
In this stage, chronic inflammation, accompanied by T-cell response, causes tissue damage 
where the continuous replacement of hepatocytes is initially achieved by differentiated hepatocytes, 
which eventually become depleted and are replaced by the recruitment of non-epithelial cells in the 
liver [18]. While their activation and proliferation initially serves to support the immune response 
and the regeneration of the tissue, during chronic liver damage and with increasing inflammation, 
their expansion predominates and they gradually replace epithelial structures in the organ. 
Inflammation/injury induces pro-inflammatory cytokines like tumor-necrosis factor-alpha (TNFα) 
and interleukin 6 (IL-6) by activating Kupffer cells and liver-derived macrophages. The activation of 
pro-inflammatory cytokines like TNFα and Il-6 can induce both pro-apoptotic and anti-apoptotic 
effects in injured liver tissue [41,42]. A pro-apoptotic response would, typically, be triggered by 
inflammation/necrosis that triggers Toll-like receptor (TLR) signaling to induce Kupffer cells to 
synthesize pro-inflammatory cytokines like TNFα, IL-6, and interferon alpha (IFNα), that recruit 
natural killer cells (NKs) to promote TNF-related apoptosis-inducing ligand (TRAIL)[43–45] (see 
Schematic 2, pathway 9). 
Alternatively, an anti-apoptotic response results from the activation of the canonical nuclear 
factor-κB (NFκB) inflammation pathway [46]. Injury triggers HSC/Kupffer cell stimulation of 
chemokines like TNFα and IL-6 that induce TLR signaling in hepatocytes. TLR signaling then 
activates the inhibitor of kappa kinase (IKK) complex to phosphorylate the IαKα/p65:p50 bound 
complex in the cytoplasm that leads to the accumulation of transcription factors p65:p50 in the 
nucleus. This accumulation, in turn, promotes an anti-apoptotic response [41,47,48] (see Schematic 2 
pathway 10). 
In CHB, a deficiency in interferon can block the immune response by subduing TLR expression, 
and the HBx protein can stimulate TGF-β1 to induce T-cell regulators to subdue the immune response 
[49,50]. Persistent activation of the NFκB pathway in HBV infection is orchestrated by way of TLRs 
that bind to HBV proteins (e.g., HBx) and activate the NFκB pathway. Typically HBV proteins bind 
to TLR-4/7/9 and recruit the myeloid differentiation primary response adaptor protein (MYD88) to 
activate tumor necrosis factor receptor (TNF-R)-associated factor 6 (TRAF6) via transforming growth 
factor beta-activated kinase 1 (TAK1), to activate the inhibitor of nuclear factor kappa-B kinase (IKK 
Pathway
1: HBx p53/miR34 CCL22 Tregs T-Cells HBV Replication
2: HBx miR-155 SOCSI JAK/STAT HBV Replication (Augmenting IFN signalling-TLR)
3: HBx miR-155 C/EBP Enh11/core promoter HBV transcripts
4: HBx miR-122 Cyclin G1 p53 binding Enh1/core promoter HBV
5: HBV miR-122 HO-1 HBV cccDNA
6: HBV HBV-miR-3 HBc mRNA HBV expression
7: HBx miR-372 CREB Enh1/core promoter HBV transcripts
8: HBx miR-372 NFIB Enh1/core promoter HBsAg, HBeAg
Symbols: Blocks Fails to block Promotes Fails to promote Increased Decreased
Scheme 1. HBx-mediated miRNA pathways i earl /c ro ic BV infection. CCL22: C-C motif
chemokine 22; S : ressor of cytokine signaling 1; C/EBP: CCAAT/enhancer-bi ding protein;
HO1: heme ox ; : c- P-response element binding protein.
Upregulation of iR-155 by HBx results in the downregulation of suppressor of cytokine
signaling-1 (SOCSI) expression contributing to increased JAK/STAT signaling, leading to the suppression
of HBV infection by augmenting interferon (IFN) signaling [30] (see Scheme 1, pathway 2). Alternatively,
HBx upregulated miR-155 also subdues HBV replication by blocking the CCAAT/enhancer-binding
protein (C/EBP) that binds and activates the HBV Enhancer (Enh) 11/core promoter [31] (see Scheme 1,
pathway 3).
The liver miR-122 is widely reported as upregulated in serum following HBV infection (references
in Table 1) and is regarded as a key suppressor of HBV expression [32–34]. However, it has been
reported that HBx downregulates miR-122 and facilitates increases in HBV transcripts by failing to
block Cyclin G1, which then blocks p53 from bindi g to HBV Enh1/core promoter thus f cilitating an
incr ase in HBV expr ss on [35] (see Scheme 1, athway 4). Other studies have d monst ated that
miR-122 blocks HBV pgRNA that encodes the hepa itis B core antige (HBcAg) and viral polymerase,
and that HBV downregulated miR-122 blocks HBV replication by failing to modulate heme-oxygenase
(HO-1), which blocks HBV covalently closed circular DNA (cccDNA) [36] (see Scheme 1, pathway 5).
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Multiple miRNA directly target HBV transcripts and examples of these include
miR-184/-185/-196a/-199a-3p/-210/-217 that are all significantly upregulated [28]. Recently it was
also discovered that the HBV virion generates its own HBV-miR-2/-3 [37]. HBV-miR-3 suppresses
the hepatitis B core protein (HBc) mRNA to self-regulate HBV expression downwards [27], possibly
in order to promote its survival by way of avoiding the host immune system [28,38] (see Scheme 1,
pathway 6).
Some miRNA, like miR-372, can influence HBV expression positively and negatively depending
on their target pathways. HBx upregulated miR-372 [39,40] targets the c-AMP-response element
binding protein (CREB) from binding to HBV enhancer 1/core promoter (Enh 1/ENI-Cp) to reduce
HBV transcripts. It also targets the nuclear factor 1 B-type protein (NF1B) that fails to modulate HBV
Enh 1 (ENI-Cp), thus promoting HBV expression [28,39] (see Scheme 1, pathway 7–8).
2.2. HBV-Induced Inflammation Pathways
In this stage, chronic inflammation, accompanied by T-cell response, causes tissue damage
where the continuous replacement of hepatocytes is initially achieved by differentiated hepatocytes,
which eventually become depleted and are replaced by the recruitment of non-epithelial cells in the
liver [18]. While their activation and proliferation initially serves to support the immune response and
the regeneration of the tissue, during chronic liver damage and with increasing inflammation,
their expansion predominates and they gradually replace epithelial structures in the organ.
Inflammation/injury induces pro-inflammatory cytokines like tumor-necrosis factor-alpha (TNFα)
and interleukin 6 (IL-6) by activating Kupffer cells and liver-derived macrophages. The activation
of pro-inflammatory cytokines like TNFα and Il-6 can induce both pro-apoptotic and anti-apoptotic
effects in injured liver tissue [41,42]. A pro-apoptotic response would, typically, be triggered by
inflammation/necrosis that triggers Toll-like receptor (TLR) signaling to induce Kupffer cells to
synthesize pro-inflammatory cytokines like TNFα, IL-6, and interferon alpha (IFNα), that recruit
natural killer cells (NKs) to promote TNF-related apoptosis-inducing ligand (TRAIL) [43–45] (see
Scheme 2, pathway 9).
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inducing ligand; TAK1: transforming growth factor beta-activated kinase 1; IKKβ: inhibitor of NFκB 
kinase. 
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cytokines, interferons, and TNFs to modulate innate immune responses [51]. 
Examples of miRNA-influenced inflammation include miR-145/-148a/-200b/-200c/-455 and the 
Let-7 family [51]. Typically the Let-7 family, for instance, is downregulated in CHB by the HBx 
protein (or alternatively “mopped” up by HBV mRNA), thus preventing it from suppressing TLR4 
signaling along the interleukin-1 receptor associated kinase (IRAK1)/TRAF6/NFKB pathway, to 
induce nuclear accumulation of p65:p50 [51] that promotes STAT3, resulting in cell proliferation and 
survival [48,52] (see Schematic 3, pathway 12). Alternatively, HBx downregulates Let-7 that can also 
activate STAT3 signaling by failing to modulate the expression of inflammatory cytokines, to 
influence miRNA-mediated suppression of key tumor suppressors [53] (see Schematic 3, pathway 
13). HBx-induced upregulation of miR-21 by Il-6 mediated STAT3 signaling typically blocks tumor 
suppressors like PTEN and PDCD4 at an early stage in the inflammation–fibrosis axis and continues 
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Schematic 3, HBx-induced miRNA in inflammation pathways. TLR: toll-like receptor; IRAK1: 
interleukin-1 receptor associated kinase 1; TRAF6: tumor necrosis factor receptor associated factor 6; 
IL: interleukein; STAT3: signal transducer and activator of transcription 3; PTEN: phosphatase and 
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Pathway
9: Inflammation/injury TLR/Kupffer cell TNFα, IL-6, INFα NK TRAIL Pro-apoptotic response
10: HSC/Kupffer cell     TNFα, IL-6   TLR              IKKβ p65:p50:IκBα p65:p50 anti-apoptotic
11: HBV TLR/MYD88 TAK1 TRAF6 IKKβ p65:p50:IκBα p65:p50 anti-apoptotic
Symbols: Blocks Fails to block Promotes Fails to promote Increased Decreased
Pathway
12: HBx Let-7 TLR4/MYD88 IRAK1/TRAF6/NF-κB p65:p50 STAT3
13: HBx Let-7 family IL-6, IL-10, TLR STAT3 activated transcription
14: HBx, inflammation IL-6 STAT3 miR-21 PTEN, PDCD4
Symbols: Blocks Fails to block Promotes Fails to promote Increased Decreased
Sche e 2. Infla ation pathways in HBV-induced pathways. HSC: hepatocyte stellate cell;
TLR: toll-like receptor; TNF: tumor necrosis factor; NK: natural killer cells; TRAIL: TNF-related
apoptosis-inducing ligand; TAK1: transforming growth factor beta-activated kinase 1; IKKβ: inhibitor
of NFκB kinase.
Alternatively, an anti-apoptotic response results from the activation of the canonical nuclear
factor-κB (NFκB) inflammation pathway [46]. Injury triggers HSC/Kupffer cell stimulation of
chemokines like TNFα and IL-6 that induce TLR signaling in hepatocytes. TLR signaling then
activates the inhibitor of kappa kinase (IKK) complex to phosphorylate the IαKα/p65:p50 bound
complex in the cytoplasm that leads to the accumulation of transcription factors p65:p50 in the nucleus.
This accumulation, in turn, promotes an anti-apoptotic response [41,47,48] (see Scheme 2 pathway 10).
In CHB, a deficiency in interferon can block the immune response by subduing TLR expression, and
the HBx protein can stimulate TGF-β1 to induce T-cell regulators to subdue the immune response [49,50].
Persiste t activation of the NFκB pathway in HBV i fection is orchestrated by way of TLRs that
b to HBV proteins (e.g., HBx) and activate the NFκB pathway. Typically HBV proteins bind
to TLR-4/7/9 and r cruit the myeloid differen iation primary response adaptor protei (MYD88) to
activate tumor necrosis factor receptor (TNF-R)-associated factor 6 (TRAF6) via transforming growth
factor beta-activated kinase 1 (TAK1), to activate the inhibitor of nuclear factor kappa-B kinase (IKK
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complex), to induce nuclear translocation of p65:p50 accumulation in the nucleus, and this results in
an anti-apoptotic effect [41,49,51] (see Scheme 2 pathway 11).
MiRNA Regulating HBV-Induced Inflammation Pathways
At the commencement of the inflammation–fibrosis continuum in persistent HBV infection, a
wide range of host miRNA are deregulated (see Table 1). Many of these miRNA subtly manipulate
the host immune response to ensure both the survival and proliferation of the virus [28]. Complex
interactions between HBV, the immune system, and miRNA trigger TLR pathways that interact with
cytokines, interferons, and TNFs to modulate innate immune responses [51].
Examples of miRNA-influenced inflammation include miR-145/-148a/-200b/-200c/-455 and the
Let-7 family [51]. Typically the Let-7 family, for instance, is downregulated in CHB by the HBx protein
(or alternatively “mopped” up by HBV mRNA), thus preventing it from suppressing TLR4 signaling
along the interleukin-1 receptor associated kinase (IRAK1)/TRAF6/NFKB pathway, to induce nuclear
accumulation of p65:p50 [51] that promotes STAT3, resulting in cell proliferation and survival [48,52] (see
Scheme 3, pathway 12). Alternatively, HBx downregulates Let-7 that can also activate STAT3 signaling
by failing to modulate the expression of inflammatory cytokines, to influence miRNA-mediated
suppression of key tumor suppressors [53] (see Scheme 3, pathway 13). HBx-induced upregulation of
miR-21 by Il-6 mediated STAT3 signaling typically blocks tumor suppressors like PTEN and PDCD4
at an early stage in the inflammation–fibrosis axis and continues in the HBV-HCC stage [54–56] (see
Scheme 3, pathway 14).
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Pathway
9: Inflammation/injury TLR/Kupffer cell TNFα, IL-6, INFα NK TRAIL Pro-apoptotic response
10: HSC/Kupffer cell     TNFα, IL-6   TLR              IKKβ p65:p50:IκBα p65:p50 anti-apoptotic
11: HBV TLR/MYD88 TAK1 TRAF6 IKKβ p65:p50:IκBα p65:p50 anti-apoptotic
Symbols: Blocks Fails to block Promotes Fails to promote Increased Decreased
Pathway
12: HBx Let-7 TLR4/MYD88 IRAK1/TRAF6/NF-κB p65:p50 STAT3
13: HBx Let-7 family IL-6, IL-10, TLR STAT3 activated transcription
14: HBx, inflammation IL-6 STAT3 miR-21 PTEN, PDCD4
Symbols: Blocks Fails to block Promotes Fails to promote Increased Decreased
Scheme 3. HBx-induced miRNA in inflammation pathways. TLR: toll-like receptor; IRAK1:
interleukin-1 receptor associated kinase 1; TRAF6: tumor necrosis factor receptor associated factor 6; IL:
interleukein; STAT3: signal transducer and activator of transcription 3; PTEN: phosphatase and tensin
gene; PDCD4: programmed cell death protein 4 gene.
Table 1. Dysregulated miRNA in the HBV infection/inflammation stage (in miR alpha-numeric order).
miRNA HBV Comment Author
Let-7 fam Down Let 7a/b/c/d/e/f/g/I all downregulated by HBx protein whichinhibits IL-6, IL-10, TLR4 expression [40,51]
Let-7a-3p Up Upregulated in early stage HBV/targets DDX3X/expressioncan be downregulated in sera but upregulated in tissue [57,58]
Let-7c Up Impairs immune response and HBV evasion/targetsHDAC4/MET to enhance HBV replication via FXRA [58–60]
miR-1 Up Targets HDAC4, MET to enhance (HBV replication)HBV RE byaugmenting FXRA expression [56]
miR-10a Up
Upregulated > three-fold in HBV infection/upregulated in
sera, Targets EphA4 which is an
epithelial-mesynchymal-transition (EMT) suppressor
[58,59,61]
miR-106a Down Downregulated by HBx, targets IL-8 in CHB [40,62]
miR-122 Up Upregulated in sera for HBeAg positive patients/correlateswith HBV DNA/in sera and tissue [32,60,63,64]
Up Upregulated in CHB vs. Healthy Controls (HC)/upregulatedin CHB vs. HC sera [25,33,59,65]
Up Upregulated in HBV also HBeAg+ vs. HBeAg–/correlateswith HBV DNA/HBsAg [63,66]
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mir-122 Down Suppress HBV by targeting HBV mRNAs/targets CyclinG1/HO-1 to promote HBV infection by inhibiting HO-1
[28,35,36,67,
68]
miR-122-5p Up Upregulated in CHB/biomarker for liver injury [69]
Down Decreased level in occult HBV infection (OBI) vs. HC [70]
miR-124 Up Serum miRNA correlates with necrosis/inflammation andupregulated in CHB vs. HC/targets AQP3 [71,72]
miR-125 Up Impairs immune response and HBV evasion [56]
miR-125a-5p Up Correlates with HBsAg/HBeAg and HBV-DNA/suppressesHBV expression by blocking HBsAg mRNA/targets KLF13 [40,58,73,74]
miR-125a Up HBx upregulated in HBV infection [40,75]
miR-125b Up Upregulated in CHB sera/correlated with HBV DNA, HBsAg,HBeAg [59,63]
miR-125b-5p Up Upregulated 2.85 fold in CHB/targets STAT3 [57,58,76]
miR-1275 Up Upregulated in HBV patients/correlated with serumΥ-glutamyl transpeptidase [63]
miR-130a UpDown
Upregulated by NFκB/ Marker for OBI/upregulated vs. HC,
ASC, CHB
Targets PGC1α and PPARγ to regulate HBV
replication/possible dual role in HBV
[70]
[77]
miR-15a Down Downregulated by HBx/Suppresses HBV infection by bindingto HBx mRNA/targets TGF-β/Smad7 [28,78,79]
miR-146 Up Targets/stimulates HBx/NFκB in HBV infection [80]
miR-150 Up Upregulated > three-fold in HBV sera/downregulated in HBVasymptomatic vs. CHB [59,60,81]
miR-151-3p Up Upregulated in CHB/biomarker for liver injury [69]
miR-155 Up Blocks SOCS1 to upregulate JAK/STAT/targets C/EBPSuppresses HBV by augmenting INF signaling [30,31]
miR-16-1 Down Downregulated by HBx RNA [78]
miR-17 Down Downregulated in HBV-infected persons [40]
miR-17-92 Up HBV transactivates c-Myc to upregulate miR-17-92 whichsuppresses HBV mRNA [82]
miR-181a-d Up
Correlated with HBV DNA and HBV disease
progression/downregulates HLA-A, HBsAg by targeting
HLA-A, E2F5
[40,83–86]
miR-182 Down Downregulated in CHB leading to HBV-related cirrhosis [87]
miR-191 Up Upregulated by HBx protein [40]
miR-192 Up Upregulated in CHB vs. HC serum [65,88]
miR-192-5p Up HBV activated/correlated with HBV Replication [88,89]
miR-193a-5p Down Downregulated in A3 vs. A0 inflammation/targets SPOCK3 [90,91]
miR-193b Up Upregulated by HBx protein/directly targets Mcl-1 [40,92]
miR-196a Down Downregulated by HBx [40,83,93]
miR-196c Up Upregulated in HBV-infected persons [40]
miR-1974 Up Upregulated in CHB vs. normal liver (NL)/upregulated A3 vs.A0 inflammation [90]
miR-199a-5p Up Upregulated in early HBV-immune tolerant/HBxupregulated/Target STAT2/low in blood sera but up in tissue [40,57]
miR-20a Down Downregulated by HBx [40]
miR-200b Down Downregulated in sera (ECVs) in CHB [81]
miR-200c Down HBx reduced in HBV infection/targets nuclear factor IA tosuppress HBV replication [28,94]
miR-205 Down Targets HBx mRNA [28,95]
miR-203a Up Upregulated in HBV infection/promotes inflammation targetsIL-6, IL-8 [96]
miR-21 Up Upregulated in A3 vs. A0 inflammation/impairs immuneresponse and HBV evasion/up in CHB vs. HC serum [56,65,90]
miR-210 Up
Correlates with HBV DNA and HBsAg/marker for
necroinflammation/suppresses HBV infection by targeting
HBsAg pre-S1 region
[58,59,97,98]
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miR-215-5p Up HBV activated miRNA/correlates with HBV replication [89]
miR-221-3p Up Upregulated in early HBV/targets TBK1/upregulated in bloodsera/tissue [57]
miR-22 Up Upregulated in HBV-infected persons/correlates with HBeAg,HBeAg positive persons/correlated with miR-122 [32,63]
Up Upregulated in A0 vs. A3 inflammation/targets HDAC4, ERαto inhibit HBsAg/HBeAg [90]
miR-223-3p Up 5.55-fold upregulated in CHB in blood sera [59,76]
miR-23a/b Up Upregulated > three-fold in HBV infection/upregulated in sera [40,58,59,83]
miR-236 Up Upregulated in CHB vs. HC sera [59]
miR-30c Up Upregulated by HBx protein [40]
miR-3200 Up Upregulated in CHB leading to LC [87]
HBV-mir-3 Up Mediates HBV RE by blocking HBc mRNA to downregulateHBV virions [27]
miR-338-3p Down Downregulated in HBV [40]
miR-339 Up Upregulated in CHB leading to LC [87]
miR-34a Up Upregulated A3 vs. A0 inflammation/promotes Tregs thatblock effector T-cells [28,29,90]
miR-342-3p Up Upregulated > three-fold in HBV infection insera/HBx-induced deregulation [40,58,59,87]
miR-3613-3p Up Upregulated in CHB/Target STAT3/down in sera [57]
miR-3615 Up Upregulated in CHB leading to LC [87]
miR-371 Up Upregulated by HBx protein [40]
miR-372 Up Correlates with HBV DNA in CHB/deregulated by HBx/targetsNFIB/HNF4, RXR, and PPAR to regulate HBV transcription [39,40,99]
miR-373 Up Correlates with HBV DNA in CHB/deregulated by HBx [39,40]
miR-375 Up Upregulated > three-fold in HBV in sera [58,59]
miR-378 Down Down-regulated in HBV [40]
miR-423 Up Upregulated > three-fold in HBV infection/upregulated in sera [58,59]
miR-4485 Down Downregulated in CHB re progression to HBV-LC [87]
miR-451 Up Upregulated in CHB vs. NL/Upregulated in A3 vs. A0inflammation [90]
miR-4508 Up Upregulated in CHB leading to LC [87]
miR-4717 Down Significant upregulation of PD-1 (programmed cell death) [100]
miR-486-5p Down Downregulated in CHB vs. NL [90]
MiR-501 Up Targets HBX1P to induce HBV RE [101]
miR-548 Down Inhibits IFN-Υ1, downregulates immune response/promotesHBV [102]
miR-548d-5p Up Upregulated in A3 vs. A0 inflammation [90]
miR-602 Up Upregulated in CHB vs. HC/targets RASSFIA/ascendingupregulation on HBV-HCC continuum [103]
miR-659 Down Downregulated in A3 vs. A0 inflammation [90]
miR-711 Down Downregulated in A3 vs. A0 inflammation [90]
miR-720 Up Upregulated in HBV patients also correlates with HBeAg+HBeAg– [63]
miR-760 Up Upregulated in A3 vs. A0 inflammation [90]
miR-762 Down Downregulated in CHB vs. NL [90]
miR-767-3p Up Upregulated in A3 vs. A0 inflammation [90]
miR-885-5p Up Upregulated in CHB vs. HC [104]
miR-92a Up Upregulated > three-fold in HBV in sera/ [58,59,81]
miR-935 Up Upregulated in CHB leading to LC [87]
miR-940 Down Downregulated in CHB/downregulated in sera and tissue [57]
miR-9-5p Down Downregulated in CHB/even lower with higher fibrosis scores [105]
miR-99a Up Upregulated in HBV+ patients also HBeAg+/upregulated insera [58,59,63]
mIr-99b Up Upregulated by HBx protein [40]
NOTE: A0–A3 (low to severe liver inflammation); IL: interleukin; TLR: toll-like receptor; DDX3X: DEAD-Box
Helicase 3 X-Linked; HDAC4: Histone Deacetylase 4; FXRA: farnesoid X receptor A; CHB: chronic hepatitis B: HC:
healthy control; ASC: asymptomatic carrier; LC: cirrhosis; NL: normal liver.
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2.3. MiRNA Regulating HBV-Induced Fibrosis/Cirrhosis
In this stage, chronic tissue damage and inflammation are accompanied by the activation of
non-epithelial cells in the liver, which proliferate. Initially this activation supports the immune response
to regenerate damaged tissue, as these non-epithelial cells gradually replace epithelial structures
in the liver. This process; however, eventually manifests as fibrosis/cirrhosis where well-organized
parenchymal tissue is increasingly replaced by disorganized and dysfunctional fibrotic tissue [18].
In the inflammation–fibrosis axis, fibrogenesis is orchestrated by a complex network of common
cytokine-mediated signaling pathways that regulate the activation of hepatic stellate cells (HSCs) and
downstream extracellular matrix (ECM) proteins. These cytokines include TGF-β, platelet-derived
growth factor (PDGF), TNF-α, interferons (IFNα/β), and interleukins (IL-1/6/17) [41,42]. Of all the
different cytokine mediated pathways, upregulated TGF-B signaling is thought to be the principal
fibrogenic pathway that activates HSCs to synthesize fibrogenic materials like collagen and alpha
smooth muscle actin (α-SMA) [106–109]. In HBV-infected patients, the HBx protein has been identified
as an activator of cytokine signaling [110], notwithstanding the synergistic effect induced by chronic
inflammation, oxidative stress, and hepatocyte loss that triggers the activation of quiescent HSCs into
myofibroblasts, which are the main source of ECM production (e.g., collagen 1/111, α-SMA) in the
liver [106,107].
A hypothesized HBx-directed fibrogenic miRNA pathway involves miR-185 as follows: HBx
promotes TGFβ signaling, that blocks miR-185 that, in turn, fails to modulate Rapamycin-insensitive
companion of mammalian target of rapamycin (RICTOR/RHEB), resulting in the activation of HSCs,
ECM proteins, and the development of fibrotic tissue [111,112] (see Scheme 4, pathway 15).
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Table 2. Dysregulated miRNA in HBV-associated liver fibrosis/cirrhosis (in miR numeric order). 
MiRNA 
Deregulation Comment Author 
miR-1 Up Upregulated in late-stage fibrosis (f3–4)/targets 
ATF2/E2F3/CREB3L2/up in tissue and sera 
[57] 
miR-10b-5p Up  Upregulated advanced fibrosis vs. early 
fibrosis/targets ATF2/E2F3/CREB3L2/up in tissue and 
sera  
[57] 
miR-101 Down  Downregulated in HBV fibrosis/HBx downregulated 
via EZH2-induced methylation/suppresses TGF-B 
signaling to block collagen 
[58,119] 
 Up Suppresses TGF-β signaling to block 
collagen/upregulated in cirrhosis versus CHB 
[120] 
Pathway
15: HBx TGFβ miR-185 RICTOR/RHEB HSCs ECM fibrosis
16: HBx TGF-B smad2/3 ZEB1/2 E-Cadherin EMT, fibrosis
17: HBx miR-192/-200fam ZEB1/2 E-Cadherin EMT, fibrosis
18: TGF-β1 miR-33a inhibitory smad7 TGF-β1                      HSCs and ECM (fibrosis)
19: TGF-β HSCs miR-29b COLIA1, COL4A5, COL5A3 fibrosis
20: TGF-1 HSCs miR-27a                              PPARγ, FOXO1, APC, p53, RXRα α-SMA, COL1A2, fibrosis/cirrhosis
Symbols: Blocks Fails to block Promotes Fails to promote Increased Decreased
Scheme 4. HBx-mediated fibrosis/cirrhosis pathways. TGFβ: transforming growth factor beta; RICTOR:
rapamycin-insensitive companion of mammalian target of rapamycin; RHEB: Ras homolog enriched
in brain; HSC: hepatocyte stellate cells; ECM: extracellular matrix; ZEB1/2: zinc finger E-box-binding
homeobox1/2.
A wide rang of miRNA that modulate fibrogenesis a e deregulated in HBV-induced liver
injury from early stage reversible fibrosis to irreversible fibrosis, loss of liver function and
cirrhosis (See Table 2). miRNA directly targeting the TGF-β pathway, for example, include
miR-122/-181b/-21/-214-3p/-221-3p/-222/-29/-33a/-942. Typically, HBx-induced TGF-β signaling induces
fibrogenesis by sequestering the transcriptional ability of coSmad4 to form a complex to activate
smad2/3, thus promoting the transcription of zinc finger E-box-binding homeobox proteins (ZEB1/2),
which blocks E-cadherin formation to reduce cell adhesion and promote epithelial mesenchymal
transition (EMT) [28,113,114] (see Scheme 4, pathway 16).
Another important miRNA family that modulates fibrogenesis is the miR-200 cluster.
In HBV-related fibrogenesis, the HBx protein suppresses p53-led transcription of miR-192/-200,
which then fails to modulate ZEB1/2, blocking the transcription of E-cadherin in the WNT/β-catenin
pathway. A loss of E-cadherin is a key feature of fibrosis/EMT and occurs early in the HBV-HCC
continuum [18,28,115] (see Scheme 4, pathway 17).
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Table 2. Dysregulated miRNA in HBV-associated liver fibrosis/cirrhosis (in miR numeric order).
MiRNA Deregulation Comment Author
miR-1 Up Upregulated in late-stage fibrosis (f3–4)/targetsATF2/E2F3/CREB3L2/up in tissue and sera [57]
miR-10b-5p Up Upregulated advanced fibrosis vs. early fibrosis/targetsATF2/E2F3/CREB3L2/up in tissue and sera [57]
miR-101 Down
Downregulated in HBV fibrosis/HBx downregulated via
EZH2-induced methylation/suppresses TGF-B signaling to
block collagen
[58,119]
Up Suppresses TGF-β signaling to block collagen/upregulated incirrhosis versus CHB [120]
miR-103 Up Upregulated in cirrhosis vs. CHB [118]
miR-122 Up Upregulated in early fibrosis/significant decrease as f0–2progresses to f3–4 [33,58,81,121]
Down Downregulated in advanced f4 vs. f0–1/suppresses TGF-βpathway to block collagen [33]
miR-122-5p Up Correlates with degree of fibrogenic damage [69,122,123]
miR-1224-3p Up Upregulated in early fibrosis (f1–2)/targetELK1/AKT2/upregulated in sera/tissue [57]
miR-1227-3p Up Upregulated early fibrosis (f1–2)/targetHSPG2/PTEN/downregulated in sera [57]
miR-125b-5p Up Upregulated in cirrhosis [76]
miR-125a-5p Up Targets F1H1 in HBV-related fibrosis vs. H. Controls [124,125]
miR-126 Up Upregulated in cirrhosis vs. CHB stage [118]
miR-1275 Down Downregulated in cirrhosis vs. CHB stage [118]
miR-128 Up Upregulated in cirrhosis vs. CHB [118]
miR-130a Up Upregulated in fibrosis/f3 > f0/upregulated in cirrhosis vs.CHB/IFNs trigger JAK/STAT [118]
miR-133a Down Downregulated in cirrhosis [126]
miR-133b Up Upregulated in advanced vs. early fibrosis/targetsATF2/E2F3/CREB3L2/upregulated in sera and tissue [57]
miR-140-5p Up Upregulated in cirrhosis vs. CHB [118]
miR-141-3p Down Downregulated in cirrhosis vs. HCC [123]
miR-142-3p Up Upregulated in cirrhosis vs. CHB [118]
miR-143 Down Downregulated in advanced fibrosis vs. early fibrosis [127]
miR-146a Up Upregulated in CHB fibrosis/upregulated in cirrhosis vs.HC/HBx upregulated > CFH fiber proteins
[104,118,121,
128]
miR-148a/b Up Upregulated in cirrhosis vs. CHB [118]
miR-149-5p Down Downregulated in HBV-induced cirrhosis [129]
miR-150 Down Inhibits collagen-1 expression and HSC activation/targetsc-myb [130]
miR-151a-3p Down Downregulated as injury increases [69]
miR-151-5p Up Upregulated in cirrhosis vs. CHB/predictor of activatedHSCs [118]
miR-17 Up Upregulated in cirrhosis vs. CHB [118]
miR-17-3p Down Downregulated as injury increases/downregulated incirrhosis vs. fibrosis [129]
miR-17-92 Down MiR-17-92 family (miR-19a/b/92) downregulated inactivated HSCs [131]
miR-181b Up
Promote fibrosis via TGF-β or NF-κB pathways/correlates
with HBV DNA/downregulated in f4 vs. f1/upregulated in
cirrhosis
[58,126]
miR-185 Down TGF-1 > miR-185 > RICTOR/RHEB > HSCs > ECM >fibrosis/downregulated in HBV-induced fibrosis [111]
miR-1915 Down Downregulated in cirrhosis vs. CHB [118]
miR-19b Down Downregulated in activated HSCs/CHB led fibrosis/f3 > f0 [131]
miR-192 Down Downregulated in sera of CHB patients re ECVs [81]
miR-193-5p Down Downregulated in cirrhosis vs. HBV-HCC [123]
miR-194 Down Inhibits collagen-1 expression and HSC/targets rac1 [130]
Up Upregulated as injury increases/targets ACVR28 [132]
miR-199 Down Downregulated as injury/cirrhosis develops [126]
miR-199-5p Up Upregulated in cirrhosis vs. CHB [118]
miR-199a-3p Down Upregulated in cirrhosis vs. CHB [118]
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miR-199a Up Upregulated in HBV-led fibrosis [40]
miR-200a/b Up Upregulated in early HBV-fibrosis [40,81]
miR-20a Up Upregulated in CHB fibrosis/f3–4 < f0–2 [121]
miR-20b-5p Down Downregulated in advanced fibrosis versus earlyfibrosis/Targets p21/upregulated in sera [57]
miR-206 Down Downregulated in cirrhosis vs. HBV-HCC [123]
miR-21 Down
Downregulated in advanced fibrosis vs. early fibrosis/acts
via TGF-B/NF-kB pathways/downregulated f0–2 > f3–4 in
CHB fibrosis
[58,118,127]
Down Downregulated in cirrhosis progression [118,133]
miR-214-3p Down AUC 0.87 predictor of fibrosis/suppresses TGF-B pathwayblocks collagen [58,134]
miR-214-5p Up Upregulated in cirrhosis [126]
miR-215 Up Upregulated in cirrhosis vs. HC [104,128]
miR-221-3p Up Promotes fibrosis via TGF-B/NF-kB paths/f4 down vs. F1 [57,118]
miR-221 Down Downregulated in CHB fibrosis but/f3–4 < f0–2 [58,121]
Up Upregulated in cirrhosis [118,126]
miR-222 Up CHB fibrosis via TGF-β/NF-κB pathways/increasingsignificant upregulation from f0–4Upregulation in cirrhosis [58,121,126]
miR-222-3p Up Upregulated 13.88-fold in cirrhosis [76,118]
miR-223 Down Downregulated in advanced fibrosis vs. early fibrosis/seearticle for path [127]
miR-224 Down Downregulated in CHB led fibrosis/f3–4 significantly lessdownregulated than f0–2 [121]
Up Upregulated in cirrhosis vs. HC [104,128]
miR-23a/b Up Upregulated in cirrhosis vs. CHB [118]
miR-26a Down Increasingly downregulated in cirrhosis continuum [133]
miR-26a-5p Up Upregulated in cirrhosis vs. HBV-HCC [123]
miR-27-3p Up/Down Biomarker for cirrhosis [129]
miR-27a Up TGF-1 > miR-27a > PPARγ, FOXO1, APC, P53 and RXRα
α-SMA and COL1A2 (activated HSCs) [118]
miR-27b Up Upregulated in cirrhosis vs. CHB [118]
miR-2861 Up Upregulated stage f4 vs. f0 fibrosis [135]
miR-29a Up Upregulated in CHB fibrosis/f3–4 < f0–2 [121]
Down Increasingly downregulated as cirrhosis develops via TGF-B,NFκB [40]
miR-29b Down Blocks collagen/TGF-B/targets COL1A1, COL4A5, COL5A3 [58,117]
miR-30b/c Up Upregulated in cirrhosis vs. CHB [118]
miR-30e Down HBx-led downregulation of miR-30e >> P4HA2fibrosis/cirrhosis [118,123,136]
Down Targets IL-6R in fibrogenic pathway [134]
miR-301a Up Upregulated in cirrhosis vs. CHB [118]
miR-324-5p Up Upregulated in cirrhosis vs. CHB [118]
miR-33a Up
Stimulates TGF-B, HSCs and promotes fibrosis/targets
SMAD7 to stimulate TGF-B HSCs/upregulated in cirrhosis
vs. CHB
[116,118]
miR-331-3p Up Upregulated in cirrhosis vs. CHB [118]
miR-338-3p Up Upregulated in cirrhosis vs. CHB [118]
miR-34a/b/c Up Upregulated in HBV-led fibrosis [40]
miR-34b-3p Up Upregulated in early fibrosis/targets GRB10/PIK3CA/up insera/tissue [57]
miR-340 Up Upregulated in cirrhosis vs. CHB [118]
miR-345-3p Up Upregulated in stage f4 vs. f0 fibrosis [135]
miR-346-3p up Upregulated in early CHB induced fibrosis stages f1–2 [57]
miR-3620-3p Up Upregulated in stage f4 vs. f0 fibrosis/cirrhosis [135]
miR-3656 Up upregulated stage f4 vs. f0 fibrosis/cirrhosis [135]
miR-371a-5p Up Upregulated in stage f4 vs. f0 fibrosis/cirrhosis [135]
miR-374 Down Downregulated in advanced fibrosis vs. early fibrosis [127]
miR-374b Up Upregulated in cirrhosis vs. CHB [118]
miR-377-3p Up Biomarker for cirrhosis [129]
miR-410-3p Up Biomarker for cirrhosis [129]
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miR-424 Up Upregulated in cirrhosis vs. CHB [118]
miR-455-3p Down Downregulated in advanced fibrosis vs. earlyfibrosis/Targets p21/upregulated in sera [57]
miR-4646-5p Up Upregulated f4 vs. f0 fibrosis/cirrhosis [135]
miR-4651 Up Upregulated f4 vs. f0 fibrosis/cirrhosis [135]
miR-4695-5p Up Upregulated f4 vs. f0 fibrosis/cirrhosis [135]
miR-4800-5p Up Upregulation f4 vs. f0 fibrosis/cirrhosis [135]
miR-483-5p Down Downregulated in f3 vs. f0 fibrosis/cirrhosis [90]
miR-486-3p Down Downregulation f4 vs. f0 fibrosis/cirrhosis [135]
miR-486-5p Down Downregulated in cirrhosis vs. HBV-HCC [123]
miR-497-5p Down Downregulation f4 vs. f0 fibrosis/cirrhosis [135]
miR-499a-5p Down Downregulated in early HBV-induced fibrosis/targetCDKNIA/IKBKB/upregulated in sera [57]
miR-513-3p Up Upregulated in early cirrhosis [58,118]
miR-571 Up Upregulated in early cirrhosis [58,118]
miR-574-3p Up Upregulated in cirrhosis vs. HC [104,128]
Upregulated early cirrhosis/differentiates between cirrhosis
and HBV-HCC [118]
miR-602 Up Upregulated in cirrhosis vs. HC/increasing in HBV-HCC [103,128]
miR-615-3p Up Promotes hypersplenism/cirrhosis [137]
miR-638 Up Upregulated f4 vs. f0 fibrosis/cirrhosis [135]
miR-652 Up Upregulated in cirrhosis vs. CHB [118]
miR-671-5p Down Downregulated in advanced versus early fibrosis/targetsATF2/E2F3/CREB3L2/up in sera and tissue [57]
miR-744 Up Upregulated in cirrhosis vs. CHB [118]
miR-885-5p Up Upregulated in cirrhosis versus HC [104,128]
miR-92 Down Downregulated in CHB fibrosis/f3–f4 > f0–f2 [121]
miR-939 Down Downregulated in cirrhosis vs. CHB [118]
miR-940 Down Downregulated in cirrhosis vs. CHB [129]
miR-942 Up Upregulated in activated HSCs/TGF and LPS inducedmiR-942 [138]
miR-9-5p Down Fibrosis/activates HSCs via TGFBR1/TGFBR2 [105]
miR-96-5p Up Upregulated in advanced fibrosis vs. early fibrosis/targetsATF2/E2F3/CREB3L2/up in sera and tissue [57]
NOTE: f0–4 (fibrosis stage levels).
HBx-induced TGF signaling in the early phase of liver disease also promotes the increase in
ECM, as a result of TGF-β1 upregulation of miR-33a to block inhibitory SMAD7, thus promoting
Rsmad-induced TGF-β1, HSCs, ECM, and fibrosis [116] (see Scheme 4, pathway 18).
Collagen is a key downstream fibrogenic product of TGF signaling and cytokines like TFG-β,
IL4/13, for instance, trigger TGF-β1-activated smad3, Stat6 to transcribe collagen type 1 alpha chain
2 (COL1A2) [112]. TGF signaling typically employs miRNA to amplify the production of collagen.
For example, TGF-β activation of HSCs can downregulate miR-29b that then fails to modulate the
expression of collagen [117] (see Scheme 4, pathway 19). TGF-β1-activated HSCs also enhance the
expression of miR-27a, which suppresses antagonists of α-SMA and collagen like PPARΥ, FOXOI,
APC, p53, and RXRα to promote fibrogenesis [118] (see Scheme 4, pathway 20).
2.4. HBV Deregulated MiRNA in HBV-HCC
In this stage, persistent HBV infection, chronic inflammation, oxidative stress, and cirrhosis can
dysregulate a wide range of host gene expression by initiating deletions, amplifications, mutations,
epigenetic changes, or by targeting miRNA loci or their transcription factors [139]. In this disrupted
tissue, HBV-HCC may develop from cells that are able to survive in cirrhotic livers and that are more
resistant to adverse conditions, viral infection, and apoptosis [18]. In this regard, the HBx protein
is thought to play a key role in the development of HCC because it can inhibit the TP53 function
in early carcinogenesis, and may contribute to the accumulation of aberrant replacement cells by
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downregulating apoptosis [18,140]. The HBx transactivating protein promotes cell cycle progression,
inactivates negative growth regulators, tumor suppressors, and senescence-related factors [141,142].
2.4.1. HBV–HBx-Downregulated MiRNA in HBV-HCC
In general, downregulated miRNAs lose their ability to modulate oncoprotein expression.
In HBV-infected persons, the HBx protein downregulates a wide range of miRNA (see Table 3) that
then fail to modulate host oncogenic target genes and/or epigenetic mechanisms [143,144]. In Table 3,
for example, key HBx-downregulated liver miRNA, like miR-122, typically fail to modulate oncogenic
cell cycle proteins (cyclins/ β-catenin/ADAM 10 and 17/BCL-W), while Let-7 fails to suppress oncogenic
proteins involved in angiogenesis, growth, and migration (STAT3/RAS/C-MYC/BCL-Xl). Another well
cited miRNA that is downregulated by the HBx protein is miR-148a, which also fails to suppress
oncogenic expression in the P13/MAPK pathway (see Figure 1).
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Table 3. HBV–HBx-downregulated miRNA in HBV-HCC (in alpha-numeric order).
miRNA Expression Target Gene Function Reference
let-7 fam Down STAT3/RAS/HMGA2C-MYC/IL-6/IL-10/TLR-4/COL1A2/NGF,BCL-XL Angiogenesis/growth/migration/inflammation/HBx repression [51,52,145,146]
miR-1 Down EDN1/PI3K/AKT/HDAC4/MET Angiogenesis, migration, invasion/modulates HBV replication [147–149]
miR-101 Down DNMT3A/RASSF1/PRDM2/GSTP1/FOS/MCL-1/EZH2 Proliferation/migration/invasion, increases HBVreplication/induce DNA methylation [120,150–153]
miR-101-3p Down ND, RAP1B/MCL-1,SOX9 Inhibits HBV, proliferation/migration/promotes apoptosis [154,155]
miR-122 Down β-CATENIN EMT, cell migration, invasion and metastasis. Downregulatedby HBx DNA methylation [28,156]
Down CCNG1 modulated p53/GLD2 Promotes cell cycle progression/increases HBV replication [35,157–159]
Down NDRG3/GALNT10 Cyclin G1/PTTG1 Promotes apoptosis/blocks cell proliferation/invasion [68,143,160,161]
Down PBF/ADAM10/Cyclin G1/Igf1R/ADAM 17/BCL-W/NDRG3 Modulates proliferation, invasion, apoptosis [28,35,68,162,163]
miR -124 Down STAT3 and PIK3CA Suppresses cell proliferation [164]
miR-125b Down SMAD2/4/SIRTUIN7/SUV39H1/LIN28B/PIGF Modulates EMT, growth, migration, and invasion [28,165]
miR-132 Down AKT Enhances cell proliferation/HBx DNA methylationdownregulates miR-132 [166]
miR-136 Down AEG-1 Cell migration, invasion, and metastasis [167]
miR-138 Down CCND3 Promotes cell cycle progression/reduces HBV replication [168]
miR-139-5p Down ZEB1/2 Modulates EMT/metastasis [28,169,170]
miR-145 Down MAP3K/CUL5/HDAC2/ADAM17 Enhances proliferation, cell cycle progression, anti-apoptosis [54,171,172]
miR-148a Down HPIP/AKT/ERK/FOXO4/ATF5/mTOR/MET/ACVR1 Down in HCC tissue/Cell proliferation, EMT, and cell migration [28,173–175]
miR-152 Down DNMT1/GSTP/CDH1/KIT Modulates DNA methylation/cellproliferation/migration/invasion, blocks HBV [176–179]
miR-15a/16-1 Down CCND1/BCL-2 Promotes cell cycle progression/proliferation [28,78,180,181]
miR-15b Down FUT2/GloboH/HNFα Enhances cell proliferation [182,183]
mIR-16 Down Cyclin D1, NCOR2 Promotes apoptosis, decreases proliferation [28,180]
miR-18a Down ERα/CTGF Enhances proliferation, regulates connective tissue growth [184,185]
miR-192 Down G1-G2 arrest/SLC39A6/SNAIL Cell cycle control/regulates metastasis [28,186,187]
miR-193b Down ING5/CCND1/ETS1 Regulate CDK2, proliferation, invasion [188,189]
miR-200 fam Down ZEB1/2 Modulates ZEB1/2 regulated E-cadherin [28,190]
miR-205 Down ACSL4/E2F1/ZEB1/2 Lipogenesis and cell proliferation/promotes EMT [28,95,191]
miR-21 Down PTEN/PIP3/AKT Down in serum/inhibits cell proliferation [54,192]
miR-216b Down IGF2BP2/IGF2/AKT/mTOR/MAPK/ERK Cell proliferation and cell migration [54,193]
miR-222 Down p27 Inhibits cell cycle progression [54]
miR-23a Down Myc/E-CADHERIN/SPROUTY2 Regulates EMT/metastasis [28,194–196]
miR-26a/c Down IL-6/IFNα/ERα/IL-6/Cyclin D2/Cyclin E2 Inhibits cell proliferation and metastasis [197–199]
miR-29c Down BCL-2/MCL-1/TNFA1P3 Inhibits cell proliferation and promotes apoptosis [200,201]
miR-338-3p Down CCND1 Promotes cell cycle progression [202,203]
miR-34a Down CCL22/MAP4K4/SIRT1/CCND1/CDK4/6/MET Modulates metastasis/growth/apoptosis [29,204–207]
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Table 3. Cont.
miRNA Expression Target Gene Function Reference
miR-363-3p Down SP1 Modulates tumor growth [28,208]
miR-373 Down E-CADHERIN EMT, cell migration, invasion, and metastasis [49]
miR-375 Down AEG-1 Cell migration, invasion, and metastasis [167]
miR-429 Down RAB18, NOTCH1 Lipogenesis/proliferation, apoptosis [209,210]
miR-520b Down HBXIP Enhancing cell proliferation [211]
miR-548p Down HBXIP, IFN-λ1 Increases growth, blocks apoptosis/immune response [102,212]
miR-661 Down MTA1/NK-κB/iNOS/NO Angiogenesis, cell proliferation, and migration [213]
Table 4. HBV–HBx-upregulated miRNA in HBV-HCC (in miR numeric order).
miRNA Expression Target Gene Function Reference
miR-1 Up MASPIN HBx-induced HBV-HCC progression [214]
miR-107 Up AXIN2/MASPIN Cell proliferation/HBV-HCC progression [214,215]
miR-125a Up ERBB2, HBsAg Suppresses HBsAg [74,178,216]
miR-143 Up FNDC3B Cell migration, invasion and metastasis [28,217]
miR-146a Up CFH/STAT1 Regulates inflammation/IFNα mediated anti- HBV efficiency [104,218,219]
miR-155 Up PTEN/SOX6/ZHX2/SOCS1 Promotes cell growth [220–222]
miR-17-92 Up E2F1 (C-MYC-repressor), Cyclin G1 Promotes HCC, blocks HBV replication, enhances proliferationand anchorage-independent growth [82,223,224]
miR-181a Up FAS, E2F5 Inhibits apoptosis, promotes cell growth [85,86]
miR-199a-5p Up CHC Promoting cell proliferation [168]
miR-203a Up RAP1A Increases inflammation/alters MAPK signaling [96]
miR-21 Up PDCD4, PTEN
Up in HCC tissue/Targets tumor suppressors/Stops
apoptosis/immune response/HBV evasion/promotes cell
growth/up in HBV-HCC vs. CHB-L Cirrhosis serum
[54–56,65,214,225,226]
miR-215 Up PTPRP Proliferation of hepatoma cells [104,186,227]
miR-221 Up ERα, DDIT4/BMF/p27/p57 Cell cycle progression (G1/S) and cell proliferation [228–230]
miR-222 Up P27(kip1)/PTEN/PPP2R2A/p27/p57 Promotes cell growth, migration [54,230–232]
miR-224 Up PAK4/MMP9 inhibitor-5/SMAD4 Enhance HBV replication, cell growth and invasion [233–235]
miR-27a Up PPARγ, FOXO1, APC, P53 and RXRα Enhances proliferation, migration, invasion [118,236]
miR-29a Up PTEN/PI3K/AKT/MMP-2 Enhancing cell migration [54,237]
miR-30c Up HMBOX1 Induces NK activity [146,238]
miR-331-3p Up ING5 Cell proliferation and apoptosis [239]
miR-545/374a Up ESRRG Cell proliferation and cell migration [240,241]
miR-602 Up RASSF1a/STAT3/MYC Cell apoptosis and proliferation, increases HBV [13,103]
miR-7 Up EGFR/RAF/EKERK/PI3K-AKT/MASPIN Inhibits cell growth [214,241–243]
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2.4.2. HBx-Upregulated MiRNA in HBV-HCC
In general, many HBx-upregulated miRNAs typically block tumor suppressor networks (see
Table 4). For example, the phosphatase and tensin homologue (PTEN) tumor suppressor is
downregulated by HBx upregulated miR-21, miR-29a, miR-221, and miR-222. Upregulated miR-21 is a
key liver miRNA that has been consistently cited as a silencer of tumor suppressors like PTEN and
PDCD4 (see references in Table 4).
3. HBV–HBx-Dysregulated MiRNA in the Principal HBV-HCC Cancer Pathways
Understanding of the molecular etiology of HCC remains incomplete [244]. Evidence to date
shows that HCC generally involves a range of disruptions of the PI3K/MAPK pathways and the p53
network that includes cell cycle controls (RB1), as well as increased WNT signaling and the inactivation
of key tumor suppressors (SOCSI) in the JAK/STAT network [18,19]. Alterations of RB1, p53, and
WNT pathways in HCC are frequently associated with HCV, HBV, and alcoholic liver cirrhosis [245].
This section focuses on examples of HBx-induced dysregulation of miRNA in HBV-HCC pathways.
3.1. Dysregulated MiRNA in the p13K/MAPK Pathway in HBV-HCC
A wide range of HBx-dysregulated miRNA (see Figure 1) play a complex regulatory role in
the activation of the PI3K/AKT/mTOR and MAPK (RAF/MEK/ERK) pathways, which are a key
feature of HCC [246,247]. Typically, a range of HBx-upregulated miRNA suppress tumor suppressor
regulation and HBx-downregulated miRNA fail to modulate oncogenic proteins. Examples of HBx
dysregulation include the upregulation of miR-17-92, miR-21 (via IL-6 activation) [55,226,248], miR-29,
miR-155-5p [222], and miR-221/-222 [54,231] to suppress PTEN regulation of AKT/mTOR expression.
Simultaneously, HBx downregulates miR1 (via EDN-1), miR-148a/-34a/26a/c and Let-7, which then fail
to modulate MET/HGF [29,147,149,173,197] and RAS/RAF/mTOR expression respectively [145,249].
The subtle HBx counter modulation of mTOR is illustrated by HBx-upregulated miR-7 that increases
inhibition of mTOR signaling [241,250], while HBx-downregulated Let-7 fails to modulate mTOR
signaling. Simultaneously, HBx-induced downregulation of miR-1 can promote HBV replication via
HDAC4-mediated stimulation of FXRα. HBx also downregulates miR-29c/-125b, resulting in reduced
controls for the transcription of BCL-2 [28,200,201] and miR-26a/-34a that modulate C-JUN/FOS/cyclinD
expression [28,197].
3.2. Dysregulated MiRNA in the WNT/β-Catenin Pathway in HBV-HCC
The upregulation of the WNT/β-catenin pathway is a frequent event in early HCC [251]. It yields
an aggressive phenotype that is implicated in the proliferation, migration, invasion, and survival of
cancer cells [244]. Figure 2 illustrates some examples of HBx-dysregulated miRNAs and their target
genes in this pathway. The HBx protein typically plays a role in enhancing WNT and β-catenin
expression while suppressing the expression of E-Cadherin. WNT signaling, for instance, is not
modulated as a result of HBx led downregulation of miR-122/148a/b [157,173,174] and Cadherin
expression is suppressed because these miRNA fail to suppress cadherin suppressors like SNAIL
1 [174]. HBx-induced upregulation of mIR-21 also enhances WNT signaling because it reduces DCC6
suppression of WNT signaling [252] and contributes to the suppression of E-cadherin by suppressing
PDCD4 expression [55]. HBx-upregulated miR-221/-222 also contributes to the suppression of cadherin
by enhancing ZEB 1/2 via blocking one of its suppressors like TRPS-1 [54,157]. Cadherin expression is
also suppressed as a result of HBx-induced downregulation of miR-200/-205/-101/34 that fails to regulate
ZEB 1/2 [95,150,190]. HBx-induced downregulation of miR-122 reduces β-catenin-led transcription in
the cytoplasm [156], while HBx upregulation of miR-155 blocks the APC tumor suppressor in the WNT
pathway, as well as suppresses HBV replication by blocking enhancer 11 to potentially hide the virus
from the host immune system [28,31].
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3.3. Dysregulated MiRNA in the TP 53 Pathway in HBV-HCC
The deregulation of multiple p53 pathways is a central event in the progression of HBV-HCC [253].
The INK4alpha/ARF locus, that encodes p14(ARF) and p16(INK4alpha) to arrest the cell cycle in the p53
and RB pathways, is frequently disrupted in HCC [254]. Figure 3 illustrates how HBx directly targets p53
expression [28,241] to influence the expression of miRNAs in this pathway. Typically, the HBx protein
downregulates miR-26a/-34a/-138/15a/16-1, that fail to modulate cyclinD/CDK 4/6 and cyclinE/CDK2
expression [78,168,197,207], as well as miR-122/-Let-7/-34a/-125b/15a/16-1 [78,145,255–258], that then
fail to modulate BCL-2-mediated suppression of CASP9/3-induced apoptosis. Similarly, HBx
downregulation of miR-101/-125b/-29a/-Let-7 exerts an anti-apoptotic effect by failing to modulate
MCL-1-mediated suppression of CASP9/3-induced apoptosis [200,255,258,259]. HBx-induced C-MYC
upregulation of miR-17-92 and miR-221/222 also contribute to the E2F-mediated downregulation
of p21/p27/p57 expression as a regulator of cyclins and cyclin-dependent kinases (CDKs) in the
network [82,223,230].
3.4. Dysregulated MiRNAs in the JAK/STAT Pathway in HBV-HCC
The aberrant methylation in the CpG island of the SOCS-1 gene is a common feature in HBV-HCC
and its silencing demonstrates its important tumor suppressor role in the JAK/STAT pathway [260].
Suppressor of cytokine signaling (SOCS-1) switches this signaling ‘off’ by means of its direct interaction
with (JAK). The loss of function of SOCS-1 is a common feature in HCC and the HBx-mediated
upregulation of miR-155 is a contributing factor in HBV-HCC (see Figure 4) [261,262]. HBx upregulated
miR-221/-203 contribute to a reduction in SOCS3 regulation of JAK/STAT signaling [263]. HBx also
downregulates Let-7, which reduces its modulation of IL-6 induced activation of JAK/STAT signaling
and mTOR mediated transcription of oncogenic proteins like C-MYC/MCL-1 [145,250,264]. However,
HBx upregulation of miR-7 [241], has been demonstrated as a control by way of suppressing mTOR
signaling in JAK/STAT pathway [250].
4. Discussion and Conclusions
This exploratory review deliberately adopts a broad focus to demonstrate the complex regulatory
role of miRNAs in the HBV-HCC continuum. Multiple knowledge gaps, exposed in this paper, prompt
further research, to clarify the complex regulatory roles of the same miRNA across the HBV-HCC
continuum. In addition, numerous miRNA target the same genes and cascades of miRNA respond
to injury and disease with differing levels of expression in tissue, serum and cell-lines. Circulating
miRNA, for instance, may originate from different cells (e.g., blood-immune) rather than an HBV or
cancer specific origin by way of secretion or cell death [265–267]. The broad focus of the paper is,
therefore, specifically adopted to highlight this complexity rather than to explain it. The key focus
of this exploratory review was, therefore, to illustrate the multiplicity of dysregulated miRNA in
clearly defined stages of pathogenesis rather than to attempt to try and explain their role in mediating
multiple targets or summarize their role across every stage of HCC pathogenesis (see miR-122/-21).
A key limitation of the study, therefore, is that it conveys an overly simplistic role of specific miRNA
in HBV-HCC pathogenesis.
The potential roles of HBx downregulated miR-124, illustrates this limitation (see Table 3).
Its various roles could include interaction with lncRNA-MALAT1 to regulate HBx-induced cancer stem
cell properties in HepG2 through PI3K/AKT signaling [268]. miR-124 also suppresses cell proliferation
and tumor growth in HCC in vitro and in vivo models by direct targeting STAT3 and PIK3CA thereby
repressing both JAK/STAT and PI3K/AKT pathways [164]. Other studies demonstrate that miR-124 can
suppress cell proliferation in HCC by targeting PIK3CA [269], as well as extracellular matrix protein
laminin gamma 1 (LAMC1), which is a key feature in HCC progression [270]. However, LAMC1 mRNA
promote malignancy by competing with miR-124 by binding with CD151 [270] and the overexpression
of LAMC1 promotes HCC progression pathway by interaction with integrin receptors on a cell surface
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to promote proliferation and metastasis in HCC [271]. Elevated LAMC1 mRNA also acts as a sponge for
miR-124 thus preventing its binding to another oncogenic membrane protein (CD151) that contributes
to its elevated expression in HCC [270].
Similarly, the figures illustrating isolated roles of HBx-dysregulated miRNA in the main HBV-HCC
pathways are clearly simplistic and only serve to demonstrate the interaction of the HBV dysregulated
miRNA and their respective targets, thus ignoring the fact that they only represent a fraction of
miRNA targeting these cancer pathways. The present review illustrates the complex range of miRNA
regulatory roles in HBV-HCC pathogenesis. It also demonstrates how miRNA manipulation of HBV
expression can be used as a tool to dissect HCC molecular pathways, and be harnessed to improve
diagnosis, prognosis, anti-viral, and anti-tumor therapeutic modalities.
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